Poniard Plans 2009 NDA For "New Generation" Platinum Chemo Picoplatin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Poniard Pharmaceuticals plans to submit an NDA for its "new generation" platinum-based cancer therapy picoplatin in the first half of 2009, CEO Jerry McMahon told investors at the Lazard Capital Markets Healthcare Conference Nov. 27